We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These ...